Budesonid/formoterol easyhaler: clinical efficiency and adherence to treatment in patients with partly controlled bronchial asthma (BA).

N. Slepchenko (Vinnytsya, Ukraine)

Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Session: Evolution or revolution in the treatment of asthma and allergies
Session type: Thematic Poster
Number: 4025
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Slepchenko (Vinnytsya, Ukraine). Budesonid/formoterol easyhaler: clinical efficiency and adherence to treatment in patients with partly controlled bronchial asthma (BA).. 4025

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Effectiveness of different models of maintenance therapy for bronchial asthma (BA) in routine clinical practice
Source: Eur Respir J 2007; 30: Suppl. 51, 70s
Year: 2007

Follow-up of patients with uncontrolled asthma: clinical features of asthma patients according to the level of control achieved (the COAS study)
Source: Eur Respir J , 49 (3) 1501885; DOI: 10.1183/13993003.01885-2015
Year: 2017



Practice-related treatment of severe persistent bronchial asthma using omalizumab in Germany: the compliance and utilisation investigation under real-life-study (XCLUSIVE)
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009


Less is more: the impact of maintenance treatment adherence in severe asthma clinical trials
Source: Eur Respir J, 53 (5) 1900599; 10.1183/13993003.00599-2019
Year: 2019



A comparison of clinical characteristics between cough variant asthma (CVA) and bronchial asthma (BA) in adult patients
Source: Annual Congress 2010 - Asthma aspect of diagnosis and criteria for follow-up
Year: 2010


Cost-effectivness of transition to new strategy of treatment in patients with bronchial asthma (BA) in Russia
Source: Eur Respir J 2001; 18: Suppl. 33, 44s
Year: 2001

Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021


Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021


Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016

Cost-effectiveness of transition to new strategy of treatment in patients with bronchial asthma (BA) in Russia
Source: Eur Respir J 2002; 20: Suppl. 38, 56s
Year: 2002

Fluticasone/salmeterol combination (FSC) is safe and provides effective long-term (52 week) control in the management of patients with persistent asthma (PA)
Source: Eur Respir J 2001; 18: Suppl. 33, 176s
Year: 2001

Reslizumab (RES) in patients (pts) with inadequately controlled asthma and elevated blood eosinophils (EOS): Analysis of two phase 3, placebo-controlled trials
Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives
Year: 2016



Efficacy of the using budesonide/formoterol in patients with bronchial asthma (BA): the study of routine clinical practice
Source: Eur Respir J 2006; 28: Suppl. 50, 499s
Year: 2006

Efficacy of omalizumab in patients with moderate-to-severe allergic asthma that is poorly controlled on GINA (1998) treatment step 3 or 4
Source: Eur Respir J 2003; 22: Suppl. 45, 203s
Year: 2003

Comparing the effects of pulmonary rehabilitation in patients with uncontrolled and partially controlled asthma
Source: International Congress 2018 – Telehealth, home rehabilitation and specific adaptations to exercise interventions in different settings
Year: 2018



Prediction of deterioration of bronchial asthma (BA) control after six months of basic anti-inflammatory therapy
Source: Annual Congress 2012 - Asthma: assessment and treatment
Year: 2012

Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials
Source: International Congress 2016 – Asthma management
Year: 2016


What clinical features underlying GINA step 1-4 drive the level of treatment in patients with asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 57s
Year: 2001

Clinical phenotypes of asthmatics who require long-term use of tiotropium for asthma control: a real-world study
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019

Long-term efficacy of a home-based airway clearance programme to improve cough severity in patients with bronchiectasis:a randomised controlled trial>
Source: International Congress 2019 – Advances in bronchiectasis and non-TB mycobacterial infections
Year: 2019